All News

In total, 8,900 small companies have won grants worth €2.4B

25 countries have agreed to back a single European research plan in neurodegenerative diseases. This is a defining moment for coordinated research says the Commissioner

The European Commission proposes to unite national funding agencies in ‘pacts’ to complete the European Research Area (ERA) by 2014 deadline - without further legislation

Only world-class science will deliver the innovation and growth Europe so desperately needs. US experience can help EU policy makers understand how to enhance R&D productivity and encourage excellence, says Paula Stephan

The $1,000 genome has arrived, providing the spur for personalised healthcare to move from theory to practice. Some existing examples of best practice and roadmaps for the future are pointing the way

Personalised healthcare promises long-term value. But how can Europe justify the upfront costs at a time of massive cuts in public spending?

Demand for fuel and power is set to keep rising strongly over the next two decades, led by the fast growing economies of China and India, projects BP

Governments can play a key role in triggering new models of collaboration, concludes the Science|Business Innovation Board

Awards programme, Feb. 21 in Brussels, is part of a Commission drive to stimulate more – and better - entrepreneurship in Europe

A new study finds that investment in computer, communications and diagnostics technologies could drastically cut the long-term care costs for breast cancer and cardiovascular disease, through better use of patient screening and adherence to treatment.

eHealth provides the means to reduce costs and improve the quality of our healthcare systems. It is now time for policy makers to take concrete measures to scale-up and accelerate adoption of technologies for real impact, says Elena Bonfiglioli

Researchers, academic policy experts and commission officials gathered in Brussels on 23 November to explore a systems approach to energy innovation at a Science|Business symposium

UK innovation strategy is changing, with a move away from across-the-board generic support, and a return to picking winners and promoting particular technologies

They are some of the largest spenders on research. But now, as pharmaceutical companies look to external collaboration and in-licensed products to fuel innovation, the internal R&D operation is having to justify the return on investment for the first time

2012 has arrived with little prospect of economic revival. New start-ups must be better prepared than ever if they are to succeed